The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://iwankecn327769.losblogos.com/37928282/glp-3-retatrutide-a-comparative-analysis